Literature DB >> 33731213

Effect of using electronic medication monitors on tuberculosis treatment outcomes in China: a longitudinal ecological study.

Ni Wang1, Lei Guo2, Hemant Deepak Shewade3,4, Pruthu Thekkur3,4, Hui Zhang1, Yan-Li Yuan5, Xiao-Meng Wang6, Xiao-Lin Wang7, Miao-Miao Sun8, Fei Huang9, Yan-Lin Zhao10.   

Abstract

BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was designed and used in 138 counties from three provinces. Previous studies showed positive results on accuracy, effectiveness, acceptability, and feasibility, but also found some ineffective implementations. In this paper, we assessed the effect of implementation of EMMs on treatment outcomes.
METHODS: The longitudinal ecological method was used at the county level with aggregate secondary programmatic data. All the notified TB cases in 138 counties were involved in this study from April 2017 to June 2019, and rifampicin-resistant cases were excluded. We fitted a multilevel model to assess the relative change in the quarterly treatment success rate with increasing quarterly EMM coverage rate, in which a mixed effects maximum likelihood regression using random intercept model was applied, by adjusting for seasonal trends, population size, sociodemographic and clinical characteristics, and clustering within counties.
RESULTS: Among all 69 678 notified TB cases, the treatment success rate was slightly increased from 93.5% [95% confidence interval (CI): 93.0-94.0] in second quarter of 2018 to 94.9% (95% CI: 94.4-95.4) in second quarter of 2019 after implementing EMMs. There was a statistically significant effect between quarterly EMM coverage and treatment success rate after adjusting for potential confounders (P = 0.0036), increasing 10% of EMM coverage rate will lead to 0.2% treatment success rate augment. Besides, an increase of 10% of elderly or bacteriologically confirmed TB will lead to a decrease of 0.4% and 0.9% of the treatment success rate.
CONCLUSIONS: Under programmatic settings, we found a statistically significant effect between increasing coverage of EMM and treatment success rate at the county level. More prospective studies are needed to confirm the effect of using EMM on TB treatment outcomes. We suggest performing operational research on EMMs that provides real-time data under programmatic conditions in the future.

Entities:  

Keywords:  Digital technology; Longitudinal study; Medication monitoring; Treatment outcome; Tuberculosis

Year:  2021        PMID: 33731213      PMCID: PMC7967105          DOI: 10.1186/s40249-021-00818-3

Source DB:  PubMed          Journal:  Infect Dis Poverty        ISSN: 2049-9957            Impact factor:   4.520


  23 in total

Review 1.  [Systematic review of directly observed therapy on tuberculosis control in China].

Authors:  Xiao-mei Wang; Jian-jun Liu; Juan Wang; Tao Wu; Si-yan Zhan
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2006-01

2.  Modelling the potential impact of adherence technologies on tuberculosis in India.

Authors:  N Arinaminpathy; D P Chin; K S Sachdeva; R Rao; K Rade; S A Nair; P Dewan
Journal:  Int J Tuberc Lung Dis       Date:  2020-05-01       Impact factor: 2.373

3.  Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting.

Authors:  Harsha Thirumurthy; Nalyn Siripong; Rachel C Vreeman; Cristian Pop-Eleches; James P Habyarimana; John E Sidle; Abraham M Siika; David R Bangsberg
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

4.  [Geographical distribution regarding the prevalence rates of pulmonary tuberculosis in China in 2010].

Authors:  Xin-xu Li; Hui Zhang; Shi-wen Jiang; Xiao-qiu Liu; Qun Fang; Jun Li; Xue Li; Li-xia Wang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2013-10

Review 5.  The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting.

Authors:  K Hemming; T P Haines; P J Chilton; A J Girling; R J Lilford
Journal:  BMJ       Date:  2015-02-06

6.  The impact of digital health technologies on tuberculosis treatment: a systematic review.

Authors:  Brian Kermu Ngwatu; Ntwali Placide Nsengiyumva; Olivia Oxlade; Benjamin Mappin-Kasirer; Nhat Linh Nguyen; Ernesto Jaramillo; Dennis Falzon; Kevin Schwartzman
Journal:  Eur Respir J       Date:  2018-01-11       Impact factor: 16.671

7.  Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis.

Authors:  Xiaoqiu Liu; Terrence Blaschke; Bruce Thomas; Sabina De Geest; Shiwen Jiang; Yongxin Gao; Xinxu Li; Elizabeth Whalley Buono; Stacy Buchanan; Zhiying Zhang; Shitong Huan
Journal:  Int J Environ Res Public Health       Date:  2017-09-25       Impact factor: 3.390

8.  Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China.

Authors:  Ni Wang; Hui Zhang; Yang Zhou; Hui Jiang; Bing Dai; Miaomiao Sun; Ying Li; Amelia Kinter; Fei Huang
Journal:  BMC Infect Dis       Date:  2019-10-15       Impact factor: 3.090

9.  Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.

Authors:  Narges Alipanah; Leah Jarlsberg; Cecily Miller; Nguyen Nhat Linh; Dennis Falzon; Ernesto Jaramillo; Payam Nahid
Journal:  PLoS Med       Date:  2018-07-03       Impact factor: 11.069

10.  A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Authors:  Marjorie Z Imperial; Payam Nahid; Patrick P J Phillips; Geraint R Davies; Katherine Fielding; Debra Hanna; David Hermann; Robert S Wallis; John L Johnson; Christian Lienhardt; Rada M Savic
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

View more
  1 in total

1.  Scale-up of a comprehensive model to improve tuberculosis control in China: lessons learned and the way forward.

Authors:  Fei Huang; Shi-Tong Huan; Qian Long; Yan-Lin Zhao
Journal:  Infect Dis Poverty       Date:  2021-03-25       Impact factor: 4.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.